Loading clinical trials...

Impact of tDCS on Cannabis Craving in Schizophrenia | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Impact of tDCS on Cannabis Craving in Schizophrenia

Impact of tDCS on Cannabis Craving in Patients With Schizophrenia and Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

NCT05784961•Centre hospitalier de Ville-Evrard, France

View on ClinicalTrials.gov

Summary

This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.

Detailed Description

The authors set up this randomized, double-blind multicenter study. 7 centers are participating in this research. After randomisation, the patient will have either the placebo or stimulation sessions, by tDCS, 5 session per day, for 5 days. The authors use the Marijuana Craving Questionnaire (MCQ) scale to determine the variation in cannabis craving and measure the impact of treatment on craving, as primary outcome. secondary objectives include assessing the effect of tDCS on the general psychopathology of schizophrenia, cannabis and tobacco addiction, and on cognitive tests assessing attention and risk taking This study will be the first known multicenter study assessing tDCS impact on cannabis craving in schizophrenia.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients (male or female) aged 18-65
•2. Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of "cannabis use disorder"
•3. Stabilized patients: total score = 80 at initial PANSS score and = 3 at the following PANSS points:
•* conceptual disorganization
•* distrust
•* hallucinatory behaviour
•* Unusual content of thought
•4. Patients without any other drug or psychotherapeutic treatment for cannabis dependence ("naive" patients)
•5. Reported cannabis use greater than three times per week in the past three years
•6. Signed consent to participate in research
+2 more criteria

Exclusion Criteria

•1. Presence of any other psychiatric disorder, as per DSM-5 criteria.
•2. Pregnancy, possible pregnancy due to lack of contraception, breastfeeding.
•3. Currently active suicidal or self-injurious ideation (suicidal or not)
•4. Patients with Serious medical codition
•5. Other "moderate" to "severe" addictions, according to DSM 5 criteria (excluding tobacco and coffee).
•6. Contraindications to tDCS (presence of intracranial metal material, intracranial hypertension, etc.).
•7. Subjects already treated by tDCS
•8. Patients under legal guardianship (except under curatorship)
•9. Patients under safeguard of justice

Locations (2)

Ch Ville Evrard

Neuilly-sur-Marne, France

Youcef Bencherif

Neuilly-sur-Marne, France

Key Dates

Start Date

March 1, 2024

Primary Completion Date

March 1, 2027

Completion Date

June 20, 2027

Last Updated

February 16, 2024

Enrollment

138

ESTIMATED participants

Conditions

SchizophreniaCannabis Use Disorder

Interventions

tDCS

DEVICE

Contacts

BOUAZIZ Noomane, MD

CONTACT

01 43 09 32 32 urcve@gmail.com

BENCHERIF Youcef, Project manager

CONTACT

01 43 09 32 32 y.bencherif@epsve.fr

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGNA

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of tDCS on Cannabis Craving in Schizophrenia

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques